Best Peptide Protocols
    ResearchJun 10, 202614 min

    Semaglutide vs Tirzepatide vs Retatrutide: GLP-1, GLP-2, GLP-3 Compared

    A head-to-head comparison of all three generations of GLP-based weight-loss peptides — mechanism, Phase 3 efficacy data, side effect profiles, and what the differences mean for research.

    Three Generations, Three Mechanisms

    The GLP peptide class has evolved rapidly across three mechanistic generations, each adding receptor targets and increasing metabolic potency:

    SemaglutideTirzepatideRetatrutide
    RL NameGLP-1 (SG)GLP-2 (TZ)GLP-3 (RT)
    ReceptorsGLP-1GLP-1 + GIPGLP-1 + GIP + Glucagon
    Mechanism typeSingle agonistDual agonistTriple agonist
    Half-life~7 days~5 days~6 days
    Dosing frequencyWeeklyWeeklyWeekly
    FDA approvalYes (obesity, T2D)Yes (obesity, T2D)No (investigational)

    Understanding why each additional receptor target matters requires examining what each receptor actually does.

    Receptor Biology: Why Each Mechanism Differs

    GLP-1 Receptor (all three)

    Glucagon-like peptide-1 receptor agonism produces the core effects shared across the class:

  1. Glucose-dependent insulin secretion (reduces hyperglycemia risk)
  2. Suppression of glucagon (reduces hepatic glucose output)
  3. Delayed gastric emptying (increases satiety, reduces food intake)
  4. Central appetite suppression via hypothalamic pathways
  5. Cardiovascular benefits (established for semaglutide in SELECT trial)

    6. GIP Receptor (tirzepatide and retatrutide)

    Glucose-dependent insulinotropic peptide receptor activation adds:

  6. Enhanced insulin secretion potentiation (synergistic with GLP-1)
  7. Adipocyte-level effects — GIP receptors on fat cells modulate lipid storage and energy balance
  8. Potentiation of GLP-1's central satiety effects
  9. Potentially improved tolerability at equivalent efficacy compared to GLP-1 alone

    10. GIP receptor effects explain a significant portion of tirzepatide's efficacy advantage over semaglutide.

    Glucagon Receptor (retatrutide only)

    Glucagon receptor agonism adds the mechanistic layer unique to retatrutide:

  10. Increased energy expenditure (resting metabolic rate elevation)
  11. Enhanced hepatic lipid oxidation (anti-NAFLD effect)
  12. Accelerated lipolysis (fat cell mobilization)
  13. Potential for greater visceral fat reduction

    14. The challenge with glucagon receptor agonism has historically been hyperglycemia — glucagon raises blood glucose. Retatrutide addresses this through GLP-1 co-agonism, which provides insulin-stimulating activity that counterbalances the glucose-raising effect of glucagon.

    Phase 3 Efficacy: The Numbers Side by Side

    Semaglutide (STEP Program)

  14. STEP-1 (non-diabetic obesity): 14.9% average weight loss at 68 weeks (2.4 mg weekly)
  15. STEP-2 (T2D): 9.6% average weight loss at 68 weeks
  16. STEP UP (higher dose exploration): Up to ~19% at higher doses
  17. SELECT trial: 20% reduction in major adverse cardiovascular events vs. placebo

    18. Tirzepatide (SURMOUNT Program)

  18. SURMOUNT-1 (non-diabetic obesity): 22.5% average weight loss at 72 weeks (15 mg weekly)
  19. SURMOUNT-2 (T2D): 15.7% average weight loss at 72 weeks
  20. Higher doses showed up to 20.9% in non-diabetic participants

    21. Retatrutide (TRIUMPH Program)

  21. TRIUMPH-1 (non-diabetic obesity): 28.3% average weight loss at 80 weeks (12 mg weekly); up to 30% with severe obesity
  22. TRIUMPH-4 (obesity + knee osteoarthritis): 28.7% weight loss at 68 weeks; 75.8% reduction in WOMAC pain scores
  23. TRANSCEND-T2D-1 (T2D): 16.8% weight loss at 40 weeks

    24. For a 250-pound research participant, this translates approximately to:

  24. Semaglutide: ~37 lbs
  25. Tirzepatide: ~56 lbs
  26. Retatrutide: ~71 lbs

    27. Side Effect Comparison

    The GI side effect profile is shared across all three — nausea, vomiting, diarrhea, and constipation — reflecting their shared GLP-1 mechanism (delayed gastric emptying).

    Side EffectSemaglutideTirzepatideRetatrutide
    Nausea~44%~31%~33%
    Diarrhea~30%~23%~30%
    Constipation~24%~22%~25%
    Vomiting~24%~16%~10–25%

    Tirzepatide's GIP receptor activity may contribute to slightly better GI tolerability than semaglutide at equivalent efficacy — a frequently noted clinical observation.

    Retatrutide adds potential dysesthesia (skin sensations) as a unique side effect, which appears related to glucagon receptor activity in peripheral tissue.

    Reconstitution Protocol Differences

    For researchers using these compounds via the injectable vial format:

    Semaglutide (GLP-1 SG)

  27. Standard vial: 5 mg or 10 mg
  28. Reconstitute in 2 mL bacteriostatic water → 2.5 mg/mL or 5 mg/mL
  29. Weekly SC dosing; typical research escalation: 0.25 mg → 0.5 mg → 1 mg → 2 mg/week

    30. Tirzepatide (GLP-2 TZ)

  30. Standard vial: 5 mg or 10 mg
  31. Reconstitute in 2 mL bacteriostatic water → 2.5 mg/mL or 5 mg/mL
  32. Weekly SC dosing; typical escalation: 2.5 mg → 5 mg → 7.5 mg → 10 mg/week

    33. Retatrutide (GLP-3 RT)

  33. Standard vial: 5 mg, 10 mg, or 15 mg
  34. Reconstitute in 2 mL → 2.5/5/7.5 mg/mL respectively
  35. Weekly SC dosing; Phase 2 protocol: 2 mg → 4 mg → 8 mg → 12 mg/week escalation

    36. All three use similar injection technique: subcutaneous injection into abdomen, thigh, or upper arm, rotating sites weekly.

    Which Compound to Select for a Given Research Protocol?

    The selection depends on the research question:

    Semaglutide (GLP-1 SG): Most established human data, FDA-approved, extensive cardiovascular outcome data (SELECT trial). Appropriate for protocols prioritizing cardiovascular endpoints or established pharmacology.

    Tirzepatide (GLP-2 TZ): Superior efficacy to semaglutide with potentially better GI tolerability. FDA-approved. Better suited for protocols requiring higher weight reduction while maintaining an approved-drug evidence base.

    Retatrutide (GLP-3 RT): Highest efficacy of the three. Investigational only — not FDA-approved. Adds energy expenditure and hepatic lipid oxidation endpoints via glucagon agonism. Appropriate for protocols exploring the frontier of triple agonism, visceral fat reduction, or comorbidity (osteoarthritis) endpoints.

    What's Next for the GLP Class

    A head-to-head Phase 3 trial of retatrutide versus tirzepatide (NCT06662383) is currently enrolling, with results expected late 2026. This will provide the first direct comparative data between the two highest-efficacy compounds in the class.

    Additionally, oral GLP-1 formulations (orforglipron, which is already in this site's capsule catalog) represent a separate development track focused on non-injectable delivery, with Phase 2 data showing up to 14.7% weight reduction at 36 weeks.

    Important Note

    This article is for educational and research reference purposes only. Semaglutide and tirzepatide are FDA-approved drugs available by prescription. Retatrutide is investigational and not FDA-approved. None of the content here constitutes medical advice.